| Literature DB >> 25750624 |
Dhavalkumar N Patel1, Han K Ho1, Liesbet L Tan2, Mui-Mui B Tan2, Qian Zhang2, Min-Yong Low3, Cheng-Leng Chan2, Hwee-Ling Koh1.
Abstract
α and β asarones are natural constituents of some aromatic plants, especially species of the genus Acorus (Araceae). In addition to reports of beneficial properties of asarones, genotoxicity and carcinogenicity are also reported. Due to potential toxic effects of β-asarone, a limit of exposure from herbal products of ~2 μg/kg body weight/day has been set temporarily until a full benefit/risk assessment has been carried out by the European Medicines Agency. Therefore, it is important to monitor levels of β-asarone in herbal products. In this study, we developed a simple, rapid and validated GC-MS method for quantitative determination of asarones and applied it in 20 pediatric herbal products after detecting high concentrations of β-asarone in a product suspected to be implicated in hepatotoxicity in a 3 month old infant. Furthermore, targeted toxicological effects were further investigated in human hepatocytes (THLE-2 cells) by employing various in vitro assays, with the goal of elucidating possible mechanisms for the observed toxicity. Results showed that some of the products contained as much as 4-25 times greater amounts of β-asarone than the recommended levels. In 4 of 10 samples found to contain asarones, the presence of asarones could not be linked to the labeled ingredients, possibly due to poor quality control. Cell-based investigations in THLE-2 cells confirmed the cytotoxicity of β-asarone (IC50 = 40.0 ± 2.0 μg/mL) which was associated with significant lipid peroxidation and glutathione depletion. This observed cytotoxic effect is likely due to induction of oxidative stress by asarones. Overall, the results of this study ascertained the usability of this GC-MS method for the quantitative determination of asarones from herbal products, and shed light on the importance of controlling the concentration of potentially toxic asarones in herbal products to safeguard consumer safety, especially when the target consumers are young children. Further investigations of the toxicity of asarones are warranted.Entities:
Keywords: adverse events; asarones; drug induced liver injury; gas chromatography-mass spectrometry; hepatotoxicity; herbal medicine
Year: 2015 PMID: 25750624 PMCID: PMC4335289 DOI: 10.3389/fphar.2015.00025
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Chemical structures of α-asarone (1) and β-asarone (2).
Figure 2GC-MS chromatograms of Product 18. The internal standard eugenol, β-asarone and α-asarone were well separated at the retention time of 5.1, 6.3, and 6.6 min respectively.
Linear regression data for the GC-MS method for quantification of asarones.
| 1 | β-asarone | 0.9993 | 156–5000 | 4.2 | 12.6 | |
| 2 | α-asarone | 0.9997 | 156–5000 | 4.6 | 13.9 |
Absolute recoveries or extraction efficiency of asarones from the herb .
| β-asarone | 400 | 94.65±4.67 | 4.94 | 95.75±5.33 | 5.57 |
| 1000 | 92.84±5.89 | 6.34 | 93.79±7.21 | 7.69 | |
| 4000 | 96.02±4.15 | 4.32 | 96.59±4.87 | 5.50 | |
| α-asarone | 400 | 96.61±6.02 | 6.23 | 94.45±6.24 | 6.61 |
| 1000 | 91.46±3.15 | 3.44 | 90.61±2.35 | 2.59 | |
| 4000 | 102.36±4.22 | 4.12 | 101.03±4.56 | 4.51 | |
Screening and quantification of β-asarone and α asarone in herbal products for children by GC-MS.
| 1 | Product 1 | Not detected | Not detected | – |
| 2 | Product 2 | Not detected | Not detected | – |
| 3 | Product 3 | 273.6 ± 21.6 | 40 ± 1.2 | |
| 4 | Product 4 | Not detected | Not detected | – |
| 5 | Product 5 | 230.9 ± 21.3 | 34.7 ± 1.2 | |
| 6 | Product 6 | 4.8 ± 0.2 | 5.0 ± 0.2 | |
| 7 | Product 7 | 11.2 ± 0.1 | 47.7 ± 3.0 | |
| 8 | Product 8 | 181.6 ± 5.4 | 106.1 ± 1.0 | – |
| 9 | Product 9 | Not detected | Not detected | – |
| 10 | Product 10 | Not detected | Not detected | – |
| 11 | Product 11 | 181.6 ± 5.4 | 106.1 ± 1.0 | unknown source |
| 12 | Product 12 | 4.3 ± 0.3 | 13.3 ± 0.1 | unknown source |
| 13 | Product 13 | 3.2 ± 0.2 | 10.9 ± 3.3 | |
| 14 | Product 14 | 241.5 ± 10.5 | 53.2 ± 1.2 | unknown source |
| 15 | Product 15 | Not detected | Not detected | – |
| 16 | Product 16 | Not detected | Not detected | – |
| 17 | Product 17 | Not detected | Not detected | – |
| 18 | Product 18 | 243.5 ± 18.2 | 144.3 ± 7.1 | unknown source |
| 19 | Product 19 | Not detected | Not detected | – |
| 20 | Product 20 | 425.7 ± 28.2 | 62.8 ± 3.1 | |
| 21 | Authentic herb A | 7679.8 ± 85.7 | 679.1 ± 20.3 |
Estimation of daily exposure levels of β-asarone in herbal products for children.
| Product 3 | Infants 6 months to 1 year: ½tsp; 1–3 years: 1 tsp; 3–6 years: 1–2 tsp; Adults: one bottle each time. 3 times a day. | ≤ 1 year: 172 | ≤ 1 year: 17–22 |
| 1–3 years: 344 | 1–3 years: 22–27 | ||
| 3–6 years: 344–688 | 3–6 years: 41 | ||
| Adults: 1067 | Adults: 115 | ||
| Product 5 | 1–6 years: ½tsp flat; 7–12 years: 1 tsp flat; Adults:1/2 bottle. 3 times daily | 1–6 years: 180 | 1–6 years: 22–41 |
| 7–12 years: 360 | 7–12 years: 41–72 | ||
| Adults: 2880 | Adults: 115 | ||
| Product 6 | 1–6 years: ½tsp flat; 7–12 years: 1 tsp flat; Adults:1/2 bottle. 3 times daily | 1–6 years: 4 | 1–6 years: 22–41 |
| 7–12 years: 8 | 7–12 years: 41–72 | ||
| Adults: 58 | Adults: 115 | ||
| Product 7 | 1–3 years: 1 tsp each time; 3–6 years:1 or 2 tsp each time; adults:1 bottle each time, 3 times a day | 1–3 years: 21 | 1–3 years: 22–27 |
| 3–6 years: 21–42 | 3–6 years: 41 | ||
| Adults: 84 | Adults: 115 | ||
| Product 11 | 1–5 years: 1 tsp each time; 5 year or more; 1–2 tsp each time. 4 times a day | 1–5 years: 370 | 1–5 years: 22–41 |
| ≥ 5 years: ≥ 370 | ≥5 years: 41–115 | ||
| Product 12 | 1–3 years: 400 mg each time; adults: 650 mg (1 bottle) each time. 2–3 times a day | 1–3 years: 3.5 | 1–3 years: 22–27 |
| Adults: 5.6–8.4 | Adults: 115 | ||
| Product 13 | One bottle each time, 2 times daily; infant mth old ½bottle each time, 2 times a day | Infants: 6.4 | Infants: 14 |
| Adults: 12.8 | Adults: 115 | ||
| Product 14 | 3 months-1 year: ½bottles each time; children 1–5 years old: 1 bottle each time; Children 5 years old and above: 1–2 bottles each time, 4 times a day. | ≤ 1 year: 193 | ≤ 1 yr: 14–22 |
| 1–5 years: 386 | 1–5 years: 22–41 | ||
| >5 years: 386–773 | >5 years: 52–115 | ||
| Product 18 | 1–5 years: 1 tsp each time; 5 years and above: 1–2 tsp each time. Four times a day. | 1–5 years: 623 | 1–5 years: 22–41 |
| >5 years: >623 | >5 years: 52–115 | ||
| Product 20 | 1–3 years: one tube per day; 4–10 years: 2 tubes per day. | 1–3 years: 128 | 1–3 years: 22–41 |
| 4–10 years: 255 | 4–10 years: 41–72 |
Figure 3The plot shows the average nanomoles of MDA per mg of protein ± standard deviation of three independent experiments upon treatment with methanol extracts of Product 20, α and β-asarones against THLE-2 cells for 24 h. Significant difference (*) was taken as p < 0.05 in comparison with untreated control cells.
Figure 4The plot shows the ratio of GSH (reduced form)/GSSG (oxidized form) (mean ± SD, . Significant difference (*) was taken as p < 0.05 in comparison with untreated control cells.
Figure 5Effects on caspase-3/7 activation and cell viability after treatment with (A) β-asarone for 6 h, (B) β-asarone for 12 h, (C) α-asarone for 6 h and (D) α-asarone for 12 h. The plot represents average % caspase-3/7 levels on primary Y-axis and % cell viability on secondary Y-axis ± standard deviation at different concentrations.